US$108 Heart Stent Lauched in China!
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- New Ocrevus Subcutaneous Injection Therapy Shows Promising Results in Multiple Sclerosis Treatmen
- Dutch Man Infected with COVID-19 for 613 Days Dies: Accumulating Over 50 Virus Mutations
- Engineered Soybeans with Pig Protein: A Promising Alternative or Pandora’s Dish?
- Severe Fever with Thrombocytopenia Syndrome (SFTS): A Tick-Borne Threat with High Mortality
US$108 Heart Stent Lauched in China!
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- What is the difference between Atorvastatin and Rosuvastatin?
- How long can the patient live after heart stent surgery?
US$108 (CN￥700） Heart Stent Lauched in China! the selected results of the centralized procurement of coronary stents by the Chinese National Organization were officially implemented in 18 provinces and cities including Beijing, Tianjin, and Liaoning on Jan 01, 2021. Patients in these places used the coronary stents after the collection.
The Chinese government organized the first batch of 18 provinces (regions) to implement centralized procurement of coronary stents, including Beijing, Tianjin, Hebei, Liaoning, Jilin, Heilongjiang, Jiangsu, Zhejiang, Fujian, Shandong, Hunan, Guangdong, Hainan, Guizhou, Yunnan, Gansu, Qinghai, Xinjiang (including the Corps). The local inventory of selected products in the first batch of 18 provinces, cities (districts), reached an average of 33% of the agreed purchase volume, which can meet the needs of medical institutions in the first month. The remaining provinces will be implemented in January 2021, and strive to allow patients to use the coronary stent after the collection.
Chen Jinfu, deputy director of the National Medical Security Administration of China: For example, the patient should have a stent. He has installed two or three. This is an unreasonable medical behavior driven by interests.
After this price space comes down, he doesn’t need more. It is useless to do more. More importantly, he has the ability to pay for the patients who needed to use coronary stents. He could not afford it before, but now he only has more than 700 yuan. He can do it completely. It has greatly expanded the accessibility of clinical medical services, so these are two benefits for the people.
The National Organization of China’s centralized procurement of coronary stents produced a selection result in early November 2020. The 10 selected varieties dropped from an average price of 13,000 yuan to about 700 yuan, a decrease of more than 90%. It is expected to save 10.9 billion yuan in medical insurance funds.
After the results of the selection were announced, various localities and departments carried out various preparations for implementation. Before December 31st, the Chinese Drug Administration conducted a full-project supervision and inspection of all selected companies, urged them to implement the main responsibility for quality and safety, and ensure the quality and safety of selected coronary stents.
China’s health department promptly organized medical institutions to sign purchase agreements, clarified production and distribution relationships, and strengthened inventory monitoring of medical institutions. The Chinese medical insurance department urges selected companies to sell online at the selected price, and at the same time introduces a medical insurance payment policy to ensure that the reduced price of coronary stents can be used and reimbursed for patients.
Approximately 1 million coronary heart disease patients are implanted with heart stents in China each year. Patients can use the selected heart stents, which will greatly reduce the burden of patients on medical treatment.
Chen Jinfu, Deputy Director of the National Medical Security Administration of China: After the price is lowered, everyone is concerned about whether companies are cutting corners. In this regard, we have a complete system design:
First, the company is the first person responsible for quality;
Second, there is quality assurance on the threshold of entry recruitment;
Third, in the process of participating in the recruitment process, the company must have a quality commitment;
Fourth, the Chinese government has quality supervision. The most important thing is that companies will regard quality as their life in terms of quality development and brand maintenance.
US$108 Heart Stent Lauched in China!
(source:internet, reference only)
Disclaimer of medicaltrend.org
